Biocon and Civica link up on Insulin Aspart access in USA

Indian drugmaker Biocon’s (BSE: 53253) Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the USA, with the news sending Biocon’s shares up nearly 4% to 333 rupees.

As part of the deal, Biocon Biologics will supply Insulin Aspart drug substance to Civica, which will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the USA, after completion of development work and clinical trials. No technology transfer is involved in the agreement.

Shreehas Tambe, chief executive and managing director, Biocon Biologics, said: “As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders. Our collaboration with Civica reflects this commitment, enabling us to expand patiept access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes. Together, we are working to ensure more patients have access to high-quality, affordable insulin.”